Your asthma is worsening despite treatment. Your genes may be why.

Your ADRB2 gene codes for the beta-2 receptor that sits on your airway smooth muscle cells. When you use a rescue inhaler like albuterol, the medication finds these receptors and tells your airways to relax and open. This is how rescue inhalers work. The better your receptors function, the faster your airways respond, and the quicker you can breathe again.

The Arg16Gly variant at position rs1042713 is incredibly common, carried by roughly 40% of the population. The Gly16 allele, which is associated with reduced bronchodilator response, means your beta-2 receptors are inherently less sensitive to beta-agonist medications. If you carry this variant, your lungs respond more slowly to albuterol and other rescue inhalers, and the effect is often weaker even after multiple doses. This isn’t about how well you use the inhaler. Your receptors themselves are less responsive.

You might notice that your rescue inhaler takes longer to work than it does for other people, or that it doesn’t give you as much relief even after waiting 15 minutes. You might find yourself using your inhaler multiple times without getting the breathing improvement you expect. You might be told your asthma is getting worse when actually your receptors just aren’t responding normally to the medication.

Interleukin-13 is a cytokine that your immune system produces in response to perceived threats. In a normal immune response, IL-13 helps coordinate defenses. In allergic asthma, IL-13 goes into overdrive, promoting eosinophil accumulation in your airways, driving mucus hypersecretion, and triggering airway remodeling where your airway walls thicken and become permanently less flexible.

IL13 variants are present in roughly 30-35% of the population, and they shift your immune system toward an allergic, Th2-skewed response. If you carry an IL13 variant, your airways are programmed to produce excessive mucus, recruit too many eosinophils, and remodel thickened walls even when you’re taking controller medications. Standard asthma inhalers don’t address the root IL-13 driven process; they just try to manage the inflammation that IL-13 is continuously promoting.

You might experience constant mucus production, a sensation of thick secretions you can’t clear, eosinophilic asthma markers in your blood work, or airway narrowing that doesn’t fully improve even with high-dose controller therapy. Your asthma might be described as eosinophilic or difficult-to-control because your immune system is genuinely programmed to maintain airway inflammation and mucus.

Interleukin-4 is one of the master cytokines that instructs your immune system to mount an allergic response. IL-4 tells your B cells to produce IgE antibodies, which then bind to mast cells and basophils throughout your airways. When you encounter an allergen, those IgE-loaded mast cells recognize it and release histamine, leukotriene, and other mediators that cause airway constriction, swelling, and mucus production.

The IL4 -590C>T variant, carried by roughly 30% of the population, increases IL-4 production and drives your immune system toward a Th2-skewed, allergic phenotype. If you carry this variant, your body is biologically programmed to mount allergic responses more strongly and mount them to more allergens than a person without the variant. You’re not choosing to be allergic to more things; your genetics are making you allergic to more things. That higher IgE production means more mast cells primed to react, and more triggers that set them off.

You might notice that you’re allergic to things that don’t bother other people, that your allergies seem worse in certain seasons even though your environment hasn’t changed, or that you have both asthma and eczema or allergic rhinitis (the atopic triad). You might have elevated IgE on bloodwork and feel like your immune system is constantly on alert.

Filaggrin is a structural protein that holds the cells of your skin and airway lining together, creating a tight physical barrier. This barrier is your first line of defense against allergens, irritants, and pathogens. When filaggrin is working normally, allergens can’t easily penetrate into the deeper layers of your airways where they would trigger mast cells and immune cells. Your barrier keeps them out.

FLG mutations like R501X and 2282del4 are carried by roughly 10% of people with European ancestry, and they disrupt this barrier function. If you carry an FLG variant, your airway barrier has structural gaps and leaks, allowing allergens to penetrate directly into your airway tissue and sensitize mast cells and immune cells. You’re not just exposed to allergens; you’re chronically exposed at a level where immune sensitization is almost inevitable. The barrier dysfunction creates a permeable membrane.

You might notice that your asthma gets worse during high pollen seasons even though you’re avoiding outdoor exposure, or that your airways are sensitive to irritants like smoke, perfume, or cold air that might not bother others as much. You might have eczema or a history of skin barrier issues. Your airways might feel raw or hyperresponsive to environmental changes.

GSTM1 is an enzyme that detoxifies electrophilic compounds, including pollutants, ozone, diesel exhaust, and oxidative stress byproducts. Your lungs are frontline organs for exposure to environmental toxins; GSTM1 is one of your main defenses. When GSTM1 is working efficiently, your airways can neutralize and eliminate irritants before they cause inflammation. When it’s not, those irritants accumulate and trigger airway inflammation and reactivity.

Roughly 40-50% of the population carries a deletion or loss-of-function variant in GSTM1, meaning they produce no functional GSTM1 enzyme at all. If you have a GSTM1 null variant, you have essentially zero ability to detoxify these compounds, and your airways accumulate oxidative stress and inflammatory byproducts continuously. Environmental triggers that might mildly irritate someone with functional GSTM1 can trigger severe asthma exacerbations in you.

You might notice that air quality affects your breathing much more severely than it does for people around you, that pollution or wildfires trigger asthma attacks, or that your asthma gets noticeably worse in urban or high-traffic areas. You might be sensitive to ozone on high-pollution days or to diesel exhaust near highways. Your airways might feel chronically inflamed even indoors.

The vitamin D receptor is a nuclear receptor that sits on immune cells, airway smooth muscle, and airway epithelial cells. When vitamin D binds to VDR, it activates genes that suppress excessive Th2 allergic responses, promote T-regulatory cells that calm down immune overreaction, and reduce inflammatory cytokine production. VDR activation is one of vitamin D’s most important mechanisms for controlling allergic and autoimmune responses.

VDR has several functional variants (FokI, BsmI, ApaI, TaqI), and certain combinations are associated with reduced VDR function or altered vitamin D responsiveness. Roughly 30-40% of the population carries VDR variants that reduce vitamin D signaling efficiency. If you have a VDR variant, your immune system may not respond normally to vitamin D, leaving you with reduced immune regulation and a bias toward allergic Th2 responses even if your vitamin D levels are technically adequate. You can have normal serum vitamin D and still have inadequate VDR signaling.

You might notice that vitamin D supplementation doesn’t improve your asthma or allergies the way it does for other people, or that your asthma is worse in winter when vitamin D levels are lower. Your immune regulation might feel fragile; you might catch infections easily or have seasonal worsening of asthma despite managing other triggers.